These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 36627212)

  • 21. Analysis of pharmacology data and the prediction of adverse drug reactions and off-target effects from chemical structure.
    Bender A; Scheiber J; Glick M; Davies JW; Azzaoui K; Hamon J; Urban L; Whitebread S; Jenkins JL
    ChemMedChem; 2007 Jun; 2(6):861-73. PubMed ID: 17477341
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety Lead Optimization and Candidate Identification: Integrating New Technologies into Decision-Making.
    Dambach DM; Misner D; Brock M; Fullerton A; Proctor W; Maher J; Lee D; Ford K; Diaz D
    Chem Res Toxicol; 2016 Apr; 29(4):452-72. PubMed ID: 26625186
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The generation, detection, and effects of reactive drug metabolites.
    Stachulski AV; Baillie TA; Park BK; Obach RS; Dalvie DK; Williams DP; Srivastava A; Regan SL; Antoine DJ; Goldring CE; Chia AJ; Kitteringham NR; Randle LE; Callan H; Castrejon JL; Farrell J; Naisbitt DJ; Lennard MS
    Med Res Rev; 2013 Sep; 33(5):985-1080. PubMed ID: 23090860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. How do the top 12 pharmaceutical companies operate safety pharmacology?
    Ewart L; Gallacher DJ; Gintant G; Guillon JM; Leishman D; Levesque P; McMahon N; Mylecraine L; Sanders M; Suter W; Wallis R; Valentin JP
    J Pharmacol Toxicol Methods; 2012 Sep; 66(2):66-70. PubMed ID: 22510338
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rationalizing Secondary Pharmacology Screening Using Human Genetic and Pharmacological Evidence.
    Deaton AM; Fan F; Zhang W; Nguyen PA; Ward LD; Nioi P
    Toxicol Sci; 2019 Feb; 167(2):593-603. PubMed ID: 30346593
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systems Toxicology: Systematic Approach to Predict Toxicity.
    Kiani NA; Shang MM; Tegner J
    Curr Pharm Des; 2016; 22(46):6911-6917. PubMed ID: 27697024
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In vitro safety pharmacology profiling: what else beyond hERG?
    Hamon J; Whitebread S; Techer-Etienne V; Le Coq H; Azzaoui K; Urban L
    Future Med Chem; 2009 Jul; 1(4):645-65. PubMed ID: 21426031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The new pre-preclinical paradigm: compound optimization in early and late phase drug discovery.
    Caldwell GW; Ritchie DM; Masucci JA; Hageman W; Yan Z
    Curr Top Med Chem; 2001 Nov; 1(5):353-66. PubMed ID: 11899102
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A Historical View and Vision into the Future of the Field of Safety Pharmacology.
    Bass AS; Hombo T; Kasai C; Kinter LB; Valentin JP
    Handb Exp Pharmacol; 2015; 229():3-45. PubMed ID: 26091634
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Exploratory safety pharmacology: a new safety paradigm to de-risk drug candidates prior to selection for regulatory science investigations.
    Cavero I
    Expert Opin Drug Saf; 2009 Nov; 8(6):627-47. PubMed ID: 19998526
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-like property concepts in pharmaceutical design.
    Di L; Kerns EH; Carter GT
    Curr Pharm Des; 2009; 15(19):2184-94. PubMed ID: 19601822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Zebrafish: an emerging technology for in vivo pharmacological assessment to identify potential safety liabilities in early drug discovery.
    Barros TP; Alderton WK; Reynolds HM; Roach AG; Berghmans S
    Br J Pharmacol; 2008 Aug; 154(7):1400-13. PubMed ID: 18552866
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatotoxicity reports in the FDA adverse event reporting system database: A comparison of drugs that cause injury
    Rana P; Aleo MD; Wen X; Kogut S
    Acta Pharm Sin B; 2021 Dec; 11(12):3857-3868. PubMed ID: 35024312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A practical guide to secondary pharmacology in drug discovery.
    Jenkinson S; Schmidt F; Rosenbrier Ribeiro L; Delaunois A; Valentin JP
    J Pharmacol Toxicol Methods; 2020 Sep; 105():106869. PubMed ID: 32302774
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Renal studies in safety pharmacology and toxicology: A survey conducted in the top 15 pharmaceutical companies.
    Benjamin A; Gallacher DJ; Greiter-Wilke A; Guillon JM; Kasai C; Ledieu D; Levesque P; Prelle K; Ratcliffe S; Sannajust F; Valentin JP
    J Pharmacol Toxicol Methods; 2015; 75():101-10. PubMed ID: 25637943
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of pharmacological agents on mitochondrial function: a growing opportunity?
    Stoker ML; Newport E; Hulit JC; West AP; Morten KJ
    Biochem Soc Trans; 2019 Dec; 47(6):1757-1772. PubMed ID: 31696924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Most Influential Physicochemical and In Vitro Assay Descriptors for Hepatotoxicity and Nephrotoxicity Prediction.
    Rana P; Kogut S; Wen X; Akhlaghi F; Aleo MD
    Chem Res Toxicol; 2020 Jul; 33(7):1780-1790. PubMed ID: 32338883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of the Potential Risk of Drugs to Induce Hepatotoxicity in Human-Relationships between Hepatic Steatosis Observed in Non-Clinical Toxicity Study and Hepatotoxicity in Humans.
    Goda K; Kobayashi A; Takahashi A; Takahashi T; Saito K; Maekawa K; Saito Y; Sugai S
    Int J Mol Sci; 2017 Apr; 18(4):. PubMed ID: 28417920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mitochondria and drugs.
    Scatena R
    Adv Exp Med Biol; 2012; 942():329-46. PubMed ID: 22399430
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of a HTS-amenable assay to detect drug-induced mitochondrial toxicity in the absence and presence of cell death.
    Swiss R; Niles A; Cali JJ; Nadanaciva S; Will Y
    Toxicol In Vitro; 2013 Sep; 27(6):1789-97. PubMed ID: 23726864
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.